OUR PIPELINE
Two modalities.
One activation strategy.
Our investigational portfolio applies radiation-responsive chemistry to targeted small-molecule and antibody-based delivery.
PIPELINE OVERVIEW · PLANNING BASIS: Q3 2026
Our development pipeline
XPADC-107, XPADC-108, XPAOC-201 and XPRDC-301 are currently in Discovery. PA-XP-102 is in Phase I. The preclinical band for XPADC-106 does not distinguish Discovery from IND-enabling and does not indicate completion. Milestones and the detailed roadmap are planned targets.
| Program | Target / Indication | Discovery | IND-enabling | Phase 1 | Phase 2/3 | Upcoming Milestones |
|---|---|---|---|---|---|---|
| GLUT1 / Pancreatic and head & neck cancers | Phase I | Phase II planned: Q2 2028 | ||||
Current stage: Phase I Program details → | ||||||
| EGFR / Head & neck and lung cancers | Preclinical | Phase I planned: Q4 2028 | ||||
Radiation-responsive cetuximab–MMAE ADC Program details → | ||||||
| HER2 / Indication to be defined | Discovery | Phase I planned: Q2 2029 | ||||
Planned HER2-directed ADC program | ||||||
| CLDN18.2 / Indication to be defined | Discovery | Phase I planned: Q4 2029 | ||||
Planned CLDN18.2-directed ADC program | ||||||
| Target / indication to be defined | Discovery | Phase I planned: Q4 2030 | ||||
Preclinical development in the company roadmap | ||||||
| Target / indication to be defined | Discovery | Preclinical work planned through 2032 | ||||
Clinical start date not specified in the roadmap | ||||||
View full 2026–2032 quarterly development plan
PLANNED DEVELOPMENT · 2026–2032
Six programs. A roadmap for development.
Quarterly development plan supplied by the company. All dates are targets and remain subject to study results, regulatory review and resources.
| Program | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | |||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Q1 | Q2 | Q3 | Q4 | Q1 | Q2 | Q3 | Q4 | Q1 | Q2 | Q3 | Q4 | Q1 | Q2 | Q3 | Q4 | Q1 | Q2 | Q3 | Q4 | Q1 | Q2 | Q3 | Q4 | Q1 | Q2 | Q3 | Q4 | |
| PA-XP-102 | Preclinical | Phase I | Phase II | US bridging study | Phase III | NDA submission | ||||||||||||||||||||||
| XPADC-106 | Preclinical | Phase I | Phase II | US bridging study | Phase III | |||||||||||||||||||||||
| XPADC-107 | Preclinical | Phase I | Phase II | US bridging study | ||||||||||||||||||||||||
| XPADC-108 | Preclinical | Phase I | Phase II | US bridging study | ||||||||||||||||||||||||
| XPAOC-201 | Preclinical | Phase I | Phase II | |||||||||||||||||||||||||
| XPRDC-301 | Preclinical | |||||||||||||||||||||||||||
PA-XP-102: current stage — Phase I. The detailed roadmap below shows the original development projections; projected dates are not actual completion dates.
The roadmap expands the two lead programs with HER2- and CLDN18.2-directed ADC projects, an AOC program and an RDC program. Stages extending to the chart boundary do not imply completion in 2032.
PIPELINE AT A GLANCE
A focused portfolio for
precision radiotherapy.
Each program combines a targeting strategy, a therapeutic payload and radiation-responsive release.
| PROGRAM | MODALITY | DESIGN | DEVELOPMENT FOCUS | STATUS |
|---|---|---|---|---|
| XP-102 | Small-molecule conjugate | GLUT1 targeting + radiation-responsive release | Pancreatic cancer; head and neck cancer | Investigational |
| XPADC-106 | Antibody–drug conjugate | Antibody targeting + radiation-responsive linker | Head and neck cancer; lung cancer | Investigational |
Development focus indicates areas under investigation and does not represent approved indications.
TARGETED PRODRUG
XP-102
Small-molecule conjugateTargeting meets radiation activation.
XP-102 is an investigational GLUT1-targeted conjugate designed for radiation-responsive release of a topoisomerase II inhibitor payload. The program brings together tumor-targeted delivery and an externally applied activation signal.
- Targeting strategy
- GLUT1
- Payload class
- Topoisomerase II inhibitor
- Activation
- Ionizing radiation
RADIATION-RESPONSIVE ADC
XPADC-106
Antibody–drug conjugateAntibody precision. A responsive linker.
XPADC-106 is an investigational cetuximab–MMAE conjugate incorporating a radiation-responsive linker. It explores antibody targeting with externally triggered payload release for solid tumors.
- Antibody
- EGFR
- Payload
- MMAE
- Activation
- Radiation-responsive linker
COLLABORATION